BOSTON–(BUSINESS WIRE)–T1D Exchange today announced the appointments of Rick Altinger and John L. Brooks III to its Board of Directors. Veteran healthcare executives with expertise in type 1 diabetes (T1D), the addition of Mr. Altinger and Mr. Brooks to the Board further supports the organization’s commitment to improving outcomes for the entire T1D population through driving real-world evidence and collaborative change.
“Rick and John bring to the T1D Exchange Board well-regarded and established track records in the area of innovative technology designed to improve lives,” said Board Chair, Keith Ryan. “Their healthcare expertise and leadership will be instrumental at this pivotal stage of our organization’s growth, and we are excited to welcome them to the team.”
“The tremendous professional achievements of Rick and John are in direct alignment with T1D Exchange’s laser focus on collecting and using real-world and clinic-derived data to drive research and innovation that will make an impact on the T1D community,” said David Walton, CEO of T1D Exchange. “From the development of our Quality Improvement Collaborative to our recent COVID-19 surveillance study and online patient registry, we continue to unlock important insights that will redefine best practices and improve care, and Rick and John will be a critical part of this initiative.”
The majority of Mr. Altinger’s 25 years of experience in the healthcare industry has been focused on the use of data and connectivity to improve care. He was part of the original leadership team at Healtheon/WebMD where he helped grow revenue from $0 to $1B and an employee base from 24 to over 5,000 individuals. Mr. Altinger was the first CEO of Glooko, a leader in diabetes digital health, data management solutions and remote monitoring solutions. He implemented and signed deals with virtually all the leading diabetes companies and led the company through multiple FDA clearances. He was responsible for growing the clinic and patient bases to over 7,000 clinics and 1.5 million patients.
Mr. Altinger received a B.S. in Mechanical Engineering and an M.S. in Engineering Management from Stanford University.
“I have extensive experience in building data-driven healthcare technology companies and was one of the early adopters of realizing the power of transforming data into insights for improved outcomes,” said Mr. Altinger. “I see incredible value in T1D Exchange’s data platform and focus on real-world outcomes, and I look forward to working closely with the management team and Board to redefine best practices and improve care for people living with T1D.”
Mr. Brooks currently serves as Managing Director at Healthcare Capital LLC, where he advises early-stage life science companies. Mr. Brooks has co-founded seven life science companies including Insulet Corporation, the Massachusetts-based tubeless insulin pump company. He previously served as a founder of Prism Venture Partners, a senior medical device executive at Pfizer, and as a senior manager at Arthur Anderson & Co and serves on the boards of various diabetes and population health organizations.
Mr. Brooks holds an M.S. in Business Administration and a BBA from the University of Massachusetts at Amherst, where he graduated cum laude, and is a certified public accountant.
“I am a firm believer that population health initiatives are critical for improving the health of individuals with chronic conditions and this is echoed by the mission of T1D Exchange,” said Mr. Brooks. “The organization’s commitment and data-driven approach to facilitate better outcomes for those living with T1D has made them a leader in the field and I look forward to working with this team to change the future of diabetes care and management.”
About T1D Exchange
T1D Exchange is dedicated to improving care for people affected by T1D through the use of real-world and clinic-derived data to drive research and innovation. The organization has amassed a comprehensive database of type 1 diabetes health information, providing clinicians, researchers, industry partners and advocates with the resources and services they need for better decision support and population health management. With an unparalleled focus on Quality Improvement, T1D Exchange is changing the future of type 1 diabetes care and treatment.
T1D Exchange was established 10 years ago with ongoing support from The Leona M. and Harry B. Helmsley Charitable Trust.
Contacts
For Media:
Lauren Arnold
Vice President
larnold@macbiocom.com
781-235-3060
